Important adverse events, worst per patient (% total patients that received therapy): possibly, probably, or definitely attributed to protocol therapies
| Toxicity . | Grade 2 . | Grade 3 . | Grade 4 . |
|---|---|---|---|
| Rituximab combined with liposomal doxorubicin (17 patients, 75 cycles) | |||
| Fever/Infusion reaction | 6 (35) | 3 (18) | — |
| Fatigue | 2 (12) | 1 (6) | — |
| Hematologic | |||
| Anemia | 4 (24) | 1 (6) | 1 (6) |
| Neutropenia | 6 (35) | 3 (18) | 1 (6) |
| CD4 lymphopenia | — | 1 (6) | — |
| Gastrointestinal | |||
| Anorexia | 2 (12) | — | — |
| Gastroesophageal reflux | 1 (6) | — | — |
| Stomatitis | 1 (6) | — | — |
| Pain | |||
| Bone pain | 1 (6) | — | — |
| Headache | 1 (6) | — | — |
| Rash | 1 (6) | — | — |
| Interferon-α (9 patients, 57.5 months) | |||
| Fatigue | 3 (33) | 2 (22) | — |
| Fever | 2 (22) | 2 (22) | — |
| Hematologic | |||
| Anemia | 2 (22) | — | — |
| Thrombocytopenia | 3 (33) | 2 (22) | 1 (11) |
| Neutropenia | 1 (11) | 5 (56) | 3 (33) |
| CD4 lymphopenia | — | 3 (33) | — |
| Gastrointestinal | |||
| Abdominal pain | 1 (11) | — | — |
| Anorexia | 1 (11) | 2 (22) | — |
| Dysgeusia | 1 (11) | — | — |
| Nausea | 1 (11) | — | — |
| Weight loss | 1 (11) | — | — |
| Infection | 1 (11) | — | — |
| Metabolic | |||
| Low albumin | 1 (11) | 1 (11) | — |
| Elevated transaminases | 1 (11) | 3 (33) | — |
| Myalgia | 3 (33) | — | — |
| Neurologic/Psychiatric | |||
| Headache | 1 (11) | — | — |
| Depression | 5 (56) | — | — |
| Insomnia | 1 (11) | — | — |
| Proteinuria | 3 (33) | — | — |
| High-dose zidovudine combined with valganciclovir (5 patients, 46 cycles) | |||
| Fatigue | 1 (20) | — | — |
| Hematologic | |||
| Neutropenia | 1 (20) | 1 (20) | 1 (20) |
| Gastrointestinal | |||
| Abdominal pain | 1 (20) | — | — |
| Anorexia | 1 (20) | — | — |
| Dyspepsia | 1 (20) | — | — |
| Nausea/Vomiting | 2 (40) | — | — |
| Toxicity . | Grade 2 . | Grade 3 . | Grade 4 . |
|---|---|---|---|
| Rituximab combined with liposomal doxorubicin (17 patients, 75 cycles) | |||
| Fever/Infusion reaction | 6 (35) | 3 (18) | — |
| Fatigue | 2 (12) | 1 (6) | — |
| Hematologic | |||
| Anemia | 4 (24) | 1 (6) | 1 (6) |
| Neutropenia | 6 (35) | 3 (18) | 1 (6) |
| CD4 lymphopenia | — | 1 (6) | — |
| Gastrointestinal | |||
| Anorexia | 2 (12) | — | — |
| Gastroesophageal reflux | 1 (6) | — | — |
| Stomatitis | 1 (6) | — | — |
| Pain | |||
| Bone pain | 1 (6) | — | — |
| Headache | 1 (6) | — | — |
| Rash | 1 (6) | — | — |
| Interferon-α (9 patients, 57.5 months) | |||
| Fatigue | 3 (33) | 2 (22) | — |
| Fever | 2 (22) | 2 (22) | — |
| Hematologic | |||
| Anemia | 2 (22) | — | — |
| Thrombocytopenia | 3 (33) | 2 (22) | 1 (11) |
| Neutropenia | 1 (11) | 5 (56) | 3 (33) |
| CD4 lymphopenia | — | 3 (33) | — |
| Gastrointestinal | |||
| Abdominal pain | 1 (11) | — | — |
| Anorexia | 1 (11) | 2 (22) | — |
| Dysgeusia | 1 (11) | — | — |
| Nausea | 1 (11) | — | — |
| Weight loss | 1 (11) | — | — |
| Infection | 1 (11) | — | — |
| Metabolic | |||
| Low albumin | 1 (11) | 1 (11) | — |
| Elevated transaminases | 1 (11) | 3 (33) | — |
| Myalgia | 3 (33) | — | — |
| Neurologic/Psychiatric | |||
| Headache | 1 (11) | — | — |
| Depression | 5 (56) | — | — |
| Insomnia | 1 (11) | — | — |
| Proteinuria | 3 (33) | — | — |
| High-dose zidovudine combined with valganciclovir (5 patients, 46 cycles) | |||
| Fatigue | 1 (20) | — | — |
| Hematologic | |||
| Neutropenia | 1 (20) | 1 (20) | 1 (20) |
| Gastrointestinal | |||
| Abdominal pain | 1 (20) | — | — |
| Anorexia | 1 (20) | — | — |
| Dyspepsia | 1 (20) | — | — |
| Nausea/Vomiting | 2 (40) | — | — |
Values are number (% total patients that received therapy).
— Indicates none observed.